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Virus-host interactions play key roles in promoting eﬃcient egress of many RNA viruses, including Ebola virus (EBOV or “e”) and
Marburg virus (MARV or “m”). Late- (L-) domains conserved in viral matrix proteins recruit speciﬁc host proteins, such as Tsg101
and Nedd4, to facilitate the budding process. These interactions serve as attractive targets for the development of broad-spectrum
budding inhibitors. A major gap still exists in our understanding of the mechanism of ﬁlovirus budding due to the diﬃculty in
detecting virus-host complexes and mapping their traﬃcking patterns in the natural environment of the cell. To address this gap,
we used a bimolecular complementation (BiMC) approach to detect, localize, and follow the traﬃcking patterns of eVP40-Tsg101
complexesinlivemammaliancells.Inaddition,weusedtheBiMCapproachalongwithaVLPbuddingassaytotestsmallmolecule
inhibitors identiﬁed by in silico screening for their ability to block eVP40 PTAP-mediated interactions with Tsg101 and subsequent
budding of eVP40 VLPs. We demonstrated the potential broad spectrum activity of a lead candidate inhibitor by demonstrating
its ability to block PTAP-dependent binding of HIV-1 Gag to Tsg101 and subsequent egress of HIV-1 Gag VLPs.
1.Introduction
Filoviruses are human pathogens that cause severe hem-
orrhagic disease and are potential agents of bioterrorism
[1, 2]. EBOV and MARV are BSL-4 agents and NIAID
Category A priority pathogens due to their association
with high fatality rates and lack of approved vaccines or
antivirals [2]. Filoviruses are enveloped, nonsegmented,
negative-strand RNA viruses with an approximately 19.0-
kilobase genome encoding the nucleoprotein (NP), VP35,
matrixprotein(VP40),attachmentglycoprotein(GP),VP30,
VP24, and RNA polymerase protein (L) [3]. VP40 is the
major component of virions, and expression of VP40 alone
in mammalian cells is suﬃcient to generate extracellular
virus-like particles (VLPs), which resemble authentic virions
in overall morphology [4–10]. Late- (L-) domain motifs
conserved in the VP40 proteins are critical for eﬃcient
egress of VLPs and virions, as they function by hijacking
speciﬁc host proteins involved in vacuolar protein sorting
(vps) pathways to facilitate the ﬁnal step of virus-cell
separation [3, 6, 10–14]. EBOV VP40 (eVP40) possesses
two L-domain motifs (PTAP and PPEY) at its N-terminus
(7-PTAPPEY-13)[ 4, 6] whereas MARV VP40 (mVP40)
and NP (mNP) contain single PPPY and PTAP L-domain
motifs, respectively [12, 15]. Various approaches such as
protein aﬃnity chromatography, GST-pulldowns, and yeast
two-hybrid screens have been used successfully to detect
these functionally relevant L-domain mediated virus-host
interactions in vitro [6, 12, 15]. For example, the PTAP L-
domain of eVP40 recruits host Tsg101, a component of the
cellular ESCRT (endosomal sorting complex required for
transport) pathway involved in sorting monoubiquitinated
proteins into multivesicular bodies (MVBs) [3, 6, 10, 12,
15–22] whereas the PPEY motif of eVP40 mediates an
interaction with host Nedd4 ubiquitin ligase [4] leading
to ubiquitination of eVP40 and enhanced VLP egress2 Advances in Virology
[4, 10, 19, 23, 24]. Despite these in vitro studies, detection
and visualization of these virus-host complexes, as well as
theintracellulartraﬃckingpatternsofthesecomplexesinthe
natural environment of the host cell remain elusive.
To address these gaps and to identify eﬀective small
molecule inhibitors of ﬁlovirus budding, we used a bimolec-
ular complementation (BiMC) assay [25–28]w i t hVenus
enhanced yellow ﬂuorescence protein (EYFP) to investigate
ﬁlovirus VP40-host interactions in mammalian cells in real
time [8]. Venus EYFP, a GFP variant containing a novel
mutation of F46L, can be split into N- and C-terminal
fragments, and reconstitution of these two EYFP fragments
mediated by a protein-protein interaction results in an
essentially irreversible ﬂuorescent signal. This approach is
useful for detecting and recording transient interaction
events, allowing for detection of short-lived and/or weakly-
associated protein-protein interactions in intact living cells
[26, 28–31] .U s i n gt h i sa p p r o a c h ,w ew e r ea b l en o to n l yt o
visualize an eVP40-Tsg101 interaction in live mammalian
cells [8], but also were able to localize and follow the
migration of eVP40-Tsg101 complexes in live cells. Lastly,
we used BiMC and VLP budding assays to assess the
speciﬁc inhibitory eﬀects of small molecule compounds
designed to block PTAP-mediated virus-host interactions
and subsequent virus budding.
2.MaterialsandMethods
2.1. Cells, Plasmids, and Antisera. Human 293T cells were
maintained in DMEM enriched with 10% FBS. All chimeric
constructs were cloned into the pCAGGS expression vec-
tor. Plasmids eVP40-WT and eVP40-ΔPT/PY have been
described previously [6]. The original MARV VP40 expres-
sion plasmid was kindly provided by Stephan Becker (Mar-
burg, Germany). Plasmid pCS2 containing full-length Venus
EYFP was generously provided by Roselyn J. Eisenberg, Gary
Cohen, and Doina Atanasiu (University of Pennsylvania
School of Dental Medicine). An HIV-1 Gag expression
construct and anti-Gag antiserum were kindly provided by
Paul Bates (University of Pennsylvania). NYFP and CYFP
fragments were PCR-ampliﬁed and fused independently
with full-length Tsg101, eVP40, mVP40, HIV Gag, or L-
domain mutants of eVP40 or Gag in pCAGGS by standard
cloning techniques [8]. Plasmid CYFP-mVP40 contains an
in-frame FLAG epitope tag between the CYFP fragment and
mVP40 ORF. Anti-eVP40 monoclonal antiserum was kindly
providedbyDr.GeneOlinger(USAMRIID,Ft.Detrick,MD)
[6]. Mouse monoclonal antibody against the FLAG epitope
(Sigma-Aldrich) was used according to the manufacturer’s
instructions. Goat polyclonal antibody against pericentrin-
B was purchased from Santa Cruz Biotechnology. Small-
molecule compound 5539-0062 (ChemDiv, San Diego, CA)
was dissolved in dimethyl sulfoxide (DMSO, FisherBiotech)
at a concentration of 10mM and stored at −20◦C.
2.2. VLP Budding Assays. Human 293T cells were singly or
co-transfected with the indicated plasmids using Lipofec-
tamine (Invitrogen) in Opti-MEM (Invitrogen) according
to the manufacturer’s directions. VLP budding assays and
western blotting were performed as described previously [8].
2.3. BiMC, Immunoﬂuorescence, and Confocal Microscopy.
Human 293T cells were grown on glass coverslips in six-well
plates and cotransfected with the indicated plasmids. At 24
hours after transfection, cells were washed with PBS, ﬁxed
with cold methanol/acetone (vol/vol, 1:1) and stained with
appropriate primary and second antibodies as indicated.
Cells were washed as described above and subsequently
stained with 4 ,6 -diamidino-2-phenylindole (DAPI) for
10min at room temperature. Cells were washed four times
with PBS, and aﬃxed to glass slides with Prolong Antifade
(Invitrogen/Molecular Probes). Slides were viewed using an
LSM-510 Meta confocal microscope (Carl Zeiss). For live cell
imaging, 293T cells were seeded in glass bottom microwell
dishes and transfected with the indicated plasmids. At 4h
after transfection, YFP ﬂuorescence was observed using
spinning-disk confocal microscopy in the presence of 5%
CO2 and humidity at 37◦C. Cells were monitored for YFP
ﬂuorescence for a period of 20–24 hours after transfection.
2.4. siRNA Transfection. Tsg101-speciﬁc siRNA and random
siRNA (used as a negative control) were purchased from
Dharmacon Inc. Transfection was performed using Lipofec-
tamine 2000 (Invitrogen) according to the manufacturer’s
instructions. Brieﬂy, 293T cells were seeded in 24-well plates
for 2 hours. Cells were then transfected with 20nM of
Tsg101-speciﬁc or random siRNA. At 24 h.p.t. the cells
were transfected a second time with identical amounts of
siRNA and the indicated plasmid(s). At 48h.p.t. the cells
were washed, ﬁxed, and YFP ﬂuorescence was detected as
described above. Cells extracts were harvested in RIPA buﬀer
and used in western blotting assays.
2.5.SmallMoleculeInhibitorsofVP40Budding. Human293T
cells seeded in 6-well plates were pretreated with either
vehicle (DMSO) alone, or compound 5539-0062 in DMSO
at the indicated concentrations for 1h at 37◦C. Cells were
subsequently transfected with the indicated plasmids. Viral
proteins in cell extracts and VLPs were detected by western
blotting as described above.
3. Results
3.1. Generation of EYFP Fusion Plasmids and Expression of
EYFP Fusion Proteins. We generated a series of plasmids
(some of which have been described previously, see [8]) for
use in the BiMC assay that contain either the N-terminal
EYFP fragment (residues 1–173, denoted NYFP), or the C-
terminal EYFP fragment (residues 174–239, denoted CYFP)
joined in-frame to host Tsg101, or to WT and L-domain
mutants of eVP40, mVP40, and HIV-1 p55-Gag (Figure 1).
All plasmids were veriﬁed by automated DNA sequencing,
and expression of all YFP fusion proteins was conﬁrmed
by western blotting [8]; (Liu and Harty, data not shown).
Importantly, fusion of the CYFP fragment to the N-termini
of all viral proteins did not aﬀect protein expression, nor theAdvances in Virology 3
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Figure 1: Schematic diagram of EYFP fusion proteins. The N-terminal half of EYFP (aa 1–173) was joined in-frame to full-length Tsg101,
and the C-terminal half of EYFP (aa 174–239) was joined in-frame to the indicated WT or L-domain mutant VP40 or HIV-1 Gag proteins. A
FLAG epitope tag is positioned at the N-terminus of mVP40-WT, and between the CYFP fragment and mVP40 in construct CYFP-mVP40-
WT. The CYFP-Gag-ΔP6 construct was made by fusing the CYFP fragment in-frame with Gag L-domain deletion mutant (the entire p6
region containing L-domain motif PTAP is deleted).
well-characterized,L-domain-dependentbuddingproperties
of these viral matrix proteins (Liu and Harty, data not
shown); [8, 32].
3.2. Detection, Localization, and Traﬃcking of eVP40-Host
Interactions in Mammalian Cells Using BiMC. Recently, we
reported that the BiMC approach could be used to detect
viral protein-protein interactions in live mammalian cells
[32]. Here, we used a similar approach to detect and map the
intracellular localization of these ﬁlovirus-host complexes,
and follow these complexes in real time as they traﬃc
through the cell. Brieﬂy, human 293T cells were cotrans-
fected with plasmids expressing NYFP-Tsg101 + CYFP-
eVP40-WT, or NYFP-Tsg101 + CYFP-eVP40-ΔPT/PY (L-
domain deletion mutant of eVP40), and cells were examined
for YFP ﬂuorescence at 24h.p.t. No background ﬂuorescence
was detected when fusion plasmids were transfected singly
([32], Liu et al., data not shown). YFP ﬂuorescence was
observed readily and reproducibly in 293T cells coexpressing
NYFP-Tsg101 + CYFP-eVP40-WT (Figure 2(a), panel a);
however, this signal was virtually absent in cells coexpressing
NYFP-Tsg101 + CYFP-eVP40-ΔPT/PY (Figure 2(a),p a n e l
b) [32]. Similar results were obtained in cell lines other
than human 293T cells including, Huh7, HeLa, and A549
cells (Liu and Harty, data not shown). The use of the L-
domain deletion mutant of eVP40 not only validates the
speciﬁcity of the observed EYFP signal (Figure 2(a), panel a),
but also conﬁrms the overall feasibility of using the BiMC
approach to detect and record these transient virus-host
interactions in mammalian cells [32]. It should be noted
that the CYFP-eVP40-ΔPT/PY protein was shown to be
functional in the BiMC assay, as it interacted with NYFP-
eVP40-WT to form eVP40-WT/eVP40-ΔPT/PY complexes
which resulted in YFP ﬂuorescent cells [32].
To further prove that the observed YFP ﬂuorescence
(Figure 2(a), panel a) was due to a speciﬁc interaction
between eVP40 and Tsg101, we cotransfected cells with
random or Tsg101-specifc siRNAs. Brieﬂy, human 293T cells
grown on coverslips in 6-well plates were mock-transfected,
or transfected with 20nM of Tsg101-speciﬁc or random
siRNA. Twenty-fourhours later,cellsweremock-transfected,
or transfected with the same amount of siRNAs along with
NYFP-Tsg101 + CYFP-eVP40 plasmids (Figure 2(a)). After
an additional 24 hours, cells were examined by confocal
microscopy for YFP ﬂuorescence. A strong YFP signal was
observed in cells expressing Tsg101/eVP40-WT in the pres-
ence of no siRNA (mock), or random siRNA (Figure 2(a)).
In contrast, YFP ﬂuorescence was virtually absent in cells
receiving Tsg101-speciﬁc siRNA (Figure 2(a)). Importantly,
the concentration of Tsg101-specﬁc siRNAs used above was
shown by western blot to knockdown expression of Tsg101
in 293T cells by >90% (Liu and Harty, data not shown; [6]).
3.3. Traﬃcking and Intracellular Localization of Tsg101/eVP40
C o m p l e x e si nL i v eC e l l s .Once the speciﬁcity of the NYFP-
Tsg101 + CYFP-eVP40-WT interaction was conﬁrmed,
we sought to determine the kinetics of association and
intracellular origin of this virus-host complex, and also
follow its movement through the cell in real time. The
YFP ﬂuorescence generated at early times p.t. in cells
co-expressing NYFP-Tsg101 + CYFP-eVP40-WT appeared
to be punctate in nature and localized adjacent to the
nucleus (Figure 2(b)). This intracellular position resem-
bled that of the microtubule organizing center (MTOC).
Therefore, we sought to determine whether the NYFP-
Tsg101 + CYFP-eVP40-WT complex was initially forming at
the MTOC by using an antibody to pericentrin-B: an MTOC
markerprotein(Figure 2(b)).Indeed,theTsg101/eVP40-WT4 Advances in Virology
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Figure 2: BiMC detecting eVP40-Tsg101 interactions and traﬃcking of Tsg101/eVP40 complex. (a) Human 293T cells grown on coverslips
in6-wellplatesweretransfectedwithNYFP-Tsg101+CYFP-eVP40-WT(a)orNYFP-Tsg101+CYFP-eVP40-ΔPT/PY.(b)Cellswerewashed,
ﬁxed, and examined for YFP ﬂuorescence by confocal microscopy at 24 hours p.t. Cells were mock-transfected, or transfected with 20nM
of Tsg101-speciﬁc or random siRNA. Twenty four hours later, cells were mock-transfected or transfected with the same amount of siRNA
along with NYFP-Tsg101 + CYFP-eVP40. After an additional 24 hours, cells were examined for YFP ﬂuorescence as described above. (b)
Colocalization eVP40-Tsg101 complexes with pericentrin. BiMC assay showing colocalization between pericentrin-B and YFP ﬂuorescence
from 293T cells expressing NYFP-Tsg101 + CYFP-eVP40-WT at 6 hours p.t. (top panel) and 24 hours p.t. (bottom panel). (c) DIC images
of a single 293T cell co-expressing NYFP-Tsg101 + CYFP-eVP40-WT at 4, 8, 12, 16, and 20 hours p.t. Blue arrows indicate Tsg101/eVP40
complex accumulation at the plasma membrane.
complex was ﬁrst visible between 3–4 hours p.t., and this
complex colocalized strongly with pericentrin-B at 6 hours
p.t. (Figure 2(b), top row). In contrast, colocalization of
the Tsg101/eVP40-WT complex with pericentrin-B was not
evident at later times p.t. (12–24 hours, Figure 2(b),b o t t o m
row). These ﬁndings suggest that the Tsg101/eVP40 complex
may traﬃc via the microtubule network to the eventual site
of budding at the plasma membrane. It should be noted that
additional cellular markers including calnexin (ER), Giantin
(cis-Golgi), and EEA1 (early endosome) were used in similarAdvances in Virology 5
colocalization experiments; however, the Tsg101/eVP40-WT
complexdidnotexhibitanysigniﬁcantlevelofcolocalization
with these host proteins (Liu and Harty, data not shown).
Further evidence supporting the movement of the
Tsg101/eVP40 complex from the MTOC to the plasma
membrane was obtained by continuous monitoring of the
YFP signal in co-transfected cells over a 16-hour period
(Figure 2(c)). Real-time images of a single cell co-expressing
NYFP-Tsg101 + CYFP-eVP40-WT at the indicated times
p.t. illustrates the changes in intracellular localization of
Tsg101-eVP40-WT complexes from their initial formation
at the MTOC between 3–4 hours after transfection, to their
enhanced accumulation at distinct patches on the plasma
membrane (Figure 2(c)). Taken together, the properties
exhibited by Tsg101-eVP40-WT complexes in the natural
environment of the cell appear to represent functional
recruitment of Tsg101 by eVP40 leading to eﬃcient budding.
3.4. Small Molecule Inhibitors of Filovirus VP40-Host Interac-
tions and VP40 VLP Budding. Viral L-domains are attractive
targets for host-oriented therapeutics which may possess
broad-spectrum activity against a plethora of L-domain
containing RNA viruses [33]. For example, a ﬁve amino
acid cyclic peptide was reported recently to disrupt the
interaction between Tsg101 and the PTAP L-domain motif
of HIV-1 Gag leading to diminished egress of Gag VLPs [34,
35]. Our strategy to identify inhibitors of ﬁlovirus budding
was to perform in silico screening of the ZINC drug-like
library (2.4 million compounds) against the NMR-derived
structure of human Tsg101 UEV domain (PDB id: 1M4P,
conformer #1) focusing on the binding pocket of the PTAP
peptide (Figure 3)[ 34, 36, 37]. The PTAP binding pocket is
outlined roughly by residues Y63, Y68, I70, M95, F142, and
S143 of Tsg101. High-throughput computational screening
was performed with the AutoDock program in the DOVIS
pipeline [38, 39]. The top 20,000 complexes from the initial
screen were minimized in CHARMM with the MMFF force
ﬁeld and reranked using Accelrys Ligscore2 [40–42].
We tested the top six scoring compounds using both
BiMC and VLP budding assays for their ability to dis-
rupt either an eVP40-Tsg101, or mVP40-Tsg101 interaction
and subsequent VLP egress. Of the six molecules tested,
compound 5539-0062 (Figure 4(a)) exhibited PTAP-speciﬁc
inhibition of eVP40 VLP egress and of eVP40-Tsg101
complex formation. Brieﬂy, human 293T cells were ﬁrst
treated for 1hour with either carrier (DMSO) alone, or
increasing concentrations of compound 5539-0062, and
then budding of eVP40 or mVP40 VLPs was evaluated
and quantiﬁed (Figures 4(b)–4(d)). Compound 5539-0062
inhibited PTAP-dependent budding of eVP40-WT VLPs by
>50% at lower concentrations, and by >90% at higher
concentrations (Figures 4(b) and 4(c)). In contrast, PTAP-
independent budding of mVP40-WT VLPs was reduced
by <2-fold at all concentrations tested (Figures 4(b) and
4(d)). Expression controls for eVP40-WT and mVP40-WT
in cells remained unaltered at all drug concentrations tested
(Figures 4(b)–4(d)). It should be noted that concentrations
of compound 5539-0062 used for the above experiments
Screen 2.4 million
drug-like compounds
from ZINC using
Autodock4/DOVIS
Select top-scoring
20,000 compounds
for further reﬁnement
Minimize w/CHARMM
and rank by LigScore2
Visually select six
compounds to
purchase
Figure 3: Strategy for computational screening of budding
inhibitors. The stereo view of the PTAP motif (green) in its binding
groove on the UEV domain of Tsg101.
exhibited no signiﬁcant toxicity in human 293T cells in
culture as determined by XTT colorimetric assay (Liu and
Harty, data not shown). Consistent with the ﬁndings of
our VLP budding assays (Figures 4(b)–4(d)), compound
5539-0062 blocked the interaction between NYFP-Tsg101 +
CYFP-eVP40-WT as determined by BiMC (Figure 4(e))a n d
quantitation of YFP ﬂuorescing cells by FACS analysis. Thus,
compound 5539-0062 was capable of speciﬁcally inhibiting
PTAP-dependent budding of eVP40 VLPs by disrupting the
eVP40-Tsg101 interaction while having no eﬀect on PTAP-
independent budding of mVP40 VLPs.
To further prove the PTAP-speciﬁc inhibitory eﬀect
of compound 5539-0062 and assess its ability to inhibit
buddingofinfectiousvirus,weinfected293Tcellswitheither
VSV-WT (containing a PPxY-type L-domain), or VSV-M40;
a VSV recombinant containing the PTAP-type L-domain
from eVP40 in place of the normal VSV PPxY-type L-
domain [18]( Table 1). In two independent experiments,
cells were infected at an MOI of 1.0 for 8 hours, and virus
released into the supernatant was harvested and titered on
BHK-21 cells. Equivalent titers of VSV-WT and VSV-M40
were obtained in the presence of vehicle (DMSO) alone
(Table 1). While the titers of VSV-WT did decrease slightly in
the presence of increasing concentrations of 5539-0062, the
titers of VSV-M40 were reproducibly reduced by 3–10-fold
more than those of VSV-WT in the presence of increasing
concentrations of compound 5539-0062 (Table 1). These
data correlate well with those shown in Figure 4, and further
support the speciﬁcity of compound 5539-0062 to inhibit
viral PTAP L-domain function by inhibiting budding of an
infectious VSV recombinant expressing the PTAP-type L-
domain from eVP40.
3.5.Compound5539-0062InhibitsHIV-1Gag-Tsg101Interac-
tion and PTAP-Dependent Gag VLP Budding. The p6 region
of HIV-1 Gag contains a well-deﬁned PTAP L-domain motif6 Advances in Virology
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Figure 4: Inhibition of VP40-Tsg101 interactions and VLP budding. (a) Chemical structure of compound 5539-0062. (b) Budding assay
and western blotting for eVP40 and mVP40 in VLPs and cell extracts from human 293T cells treated with DMSO alone, or the indicated
concentrations of PTAP-inhibitor 5539-0062. (c) Bar graph of the relative amounts of eVP40-WT in cells and VLPs (part B) determined
using Dot-Blot, LabWorks software (UVP). (d) Bar graph of the relative amounts of mVP40-WT in cells and VLPs (part B) determined
using Dot-Blot, LabWorks software (UVP). (e) BiMC of human 293T cells expressing NYFP-Tsg101 + CYFP-eVP40-WT and treated with
DMSO alone, or the indicated concentrations of PTAP-inhibitor 5539-0062. Cells were examined for YFP ﬂuorescence at 24 hour p.t., and
positive cells were quantiﬁed by FACS analysis. The average values were as follows: DMSO alone = 100%, 25µM = 84%, 50µM = 68%, and
75µM = 24%.
Table 1: Viral titers in the presence of drug 5539-0062.
5539-0062 (µM) VSV-WT VSV-M40
Exp. number 1 Exp. number 2 Exp. number 1 Exp. number 2
0.0 1.2 ×105 1.2 ×105 1.2 ×105 1.1 ×105
25.0 8.2 ×104 8.0 ×104 1.4 ×104 1.0 ×104
50.0 1.5 ×104 1.6 ×104 3.6 ×103 3.8 ×103
75.0 8.6 ×103 N.D. 6.4 ×102 N.D.
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that mediates eﬃcient budding of HIV-1 virions and Gag
VLPs by recruiting Tsg101 in a manner similar to that used
by eVP40 [16, 17, 20]. To determine whether PTAP inhibitor
5539-0062 has broad-spectrum antibudding activity, we
employed the HIV-1 Gag protein in our VLP budding assay
and generated HIV-1 Gag-YFP fusion proteins for use in
BiMC. Brieﬂy, human 293T cells were cotransfected with
NYFP-Tsg101 + CYFP-Gag-WT or CYFP-Gag-ΔP6 (PTAP
L-domain mutant) as a control (see Figure 1), and YFP
ﬂuorescence was detected at 24 hours p.t. (Figure 5(a)). Cells
co-expressing NYFP-Tsg101 + CYFP-Gag-WT displayed a
predominantly punctate YFP signal that was evident in both
perinuclear patches and at the cell periphery (Figure 5(a)).
As expected, the YFP signal was virtually absent in cells
co-expressing NYFP-Tsg101 + CYFP-Gag-ΔP6 (Figure 5(a)).
BoththeCYFP-Gag-WTandCYFP-Gag-ΔP6fusionproteins
were shown to be expressed in transfected 293T cells by
western blot (Liu and Harty, data not shown).
Next, we used both BiMC (Figure 5(b)) and VLP
budding (Figure 5(c)) assays to determine whether com-
pound 5539-0062 could inhibit a Gag-Tsg101 interaction
and subsequent egress of HIV-1 Gag VLPs in a dose-
dependent manner. Human 293T cells were treated with
vehicle (DMSO) alone or the indicated concentrations of
compound 5539-0062, and then co-transfected with NYFP-
Tsg101 + CYFP-Gag-WT (Figure 5(b)). Cells were examined
for YFP ﬂuorescence at 24 hours p.t. by confocal microscopy
(Figure 5(b)). Abundant YFP positive cells were observed in
the presence of DMSO; however, the total number of YFP
positive cells decreased with increasing concentrations of
compound 5539-0062 (Figure 5(b)). These ﬁndings indicate
that compound 5539-0062 was able to inhibit the PTAP-
mediated interaction between Tsg101 and HIV-1 Gag in a
dose-dependent manner.
Next, human 293T cells were ﬁrst treated for 1 hour with
either vehicle (DMSO) alone, or increasing concentrations
of compound 5539-0062, and then transfected with HIV-
1 p55-Gag expression plasmid (Figure 5(c)). p55-Gag was
detected by western blot and quantiﬁed in both VLPs and
cell extracts at 24hp.t. (Figure 5(c)). Budding of p55-Gag
was inhibited by compound 5539-0062 in a dose-dependent
manner as shown by decreasing levels of p55-Gag in VLPs
(Figure 5(c)). Equivalent levels of p55-Gag were maintained
in cell extracts over the entire range of inhibitor concentra-
tions (Figure 5(c)). Taken together, these data indicate that
L-domain inhibitors such as compound 5539-0062, are likely
to possess broad-spectrum antiviral activity against a wide
array of RNA viruses that depend on speciﬁc L-domain/host
interactions for eﬃcient egress and spread.
4. Discussion
Filovirus-host interactions are important for eﬃcient egress
of virus particles; however, mechanistic details of the forma-
tion, dynamics, and traﬃcking of these virus-host complexes
in the natural environment of the host cell have been elusive.
In this report, we used a BiMC approach to visualize eVP40-
Tsg101 complexes as they formed in the cell. The speciﬁcity
of this interaction was conﬁrmed by using an L-domain
deletion mutant of eVP40 and by using Tsg101 speciﬁc
siRNAs. Importantly, the NYFP-Tsg101 fusion protein was
stably expressed in mammalian cells, and CYFP-VP40 fusion
proteins retained their ability to bud independently from
cells as VLPs in an L-domain-dependent manner. The BiMC
approachisidealfordetectingweakand/ortransientprotein-
protein interactions in living cells [27, 28]. We demonstrated
that eVP40-Tsg101 complexes formed between 3–4 hours
after transfection and colocalized at early times (6hrs. p.t.)
with pericentrin-B, an MTOC marker. We postulate that the
initial eVP40-Tsg101 complexes may then migrate from the
MTOCtothesiteofbuddingattheplasmamembraneby12–
24 hours p.t. This working model correlates with previous
reports which suggested that ﬁlovirus VP40 proteins may
interact with and utilize the host cytoskeletal network during
assembly and egress [43, 44].
Elucidation of the molecular complexities and dynamics
of virus-host interactions in the natural cell environment
will enhance our ability to eﬀectively screen and validate
new antivirals [29, 31, 33]. Recent studies have identiﬁed
two compounds, FGI-104 and FGI-106, that showed activity
against ﬁloviruses in cell culture and in animals [45, 46];
however, the targets of FGI-104 and FGI-106 remain to
be determined. In addition, small molecule inhibitors of
ﬁlovirus entry have recently been identiﬁed and charac-
terized [47–49]. Viral L-domain/host interactions remain
an attractive target for the development of novel, broad-
spectrum budding inhibitors [33–35, 50]. The successful
development of the BiMC assay to assess ﬁlovirus-host inter-
actions (this manuscript) and the use of our well-established
VLPbuddingassayrepresentpowerfultoolsthatwillallowus
to screen and validate small molecule inhibitors of ﬁlovirus
budding. By using the known 3D atomic structure of Tsg101
binding to the PTAP motif, we employed an in silico strategy
to identify and rank commercially available compounds with
predicted drug-like properties that could potentially block
this interaction. From this screen, we identiﬁed compound
5539-0062 and used both BiMC and VLP budding assays to
demonstrate that this small molecule speciﬁcally inhibited
PTAP-dependent budding of eVP40 VLPs, but not PTAP-
independentbuddingofmVP40VLPs.Moreover,compound
5539-0062 also exhibited speciﬁc antiviral activity in cells
infected with a recombinant VSV (VSV-M40) expressing
the PTAP L-domain of eVP40. The reason for the low
level of inhibition of PPxY-dependent budding of VSV-
WT observed in the presence of compound 5539-0062
remains to be determined (Table 1), as does the potential
eﬀect of compound 5539-0062 on other stages of VSV
replication. The PTAP-speciﬁc inhibitory activity exhibited
by this single, ﬁrst-generation compound is encouraging
and serves as proof-of-principle for using this strategy and
the BiMC assay to identify and validate budding inhibitors.
Compound 5539-0062 could potentially be optimized to
improve binding aﬃnity by either searching for chemically
similar molecules in the commercially available databases,
or by using the structural interaction ﬁngerprint method
which involves selecting compounds which are predicted
to have the same protein-ligand interactions as 5539-00628 Advances in Virology
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Figure 5: Inhibition of HIV-1 Gag-Tsg101 interaction and VLP budding. (a) Human 293T cells grown on coverslips in 6-well plates were
transfected with NYFP-Tsg101 + CYFP-Gag-WT (panels 1 and 2) or NYFP-Tsg101 + CYFP-Gag-ΔP6 (panel 3). Cells were washed, ﬁxed,
and examined for YFP ﬂuorescence by confocal microscopy at 24 hours p.t. The image within the dotted square in panel 1 was enlarged
and shown panel 2. (b) Human 293T cells grown on coverslips in 6-well plates were transfected with NYFP-Tsg101 + CYFP-Gag-WT in
the presence of DMSO alone, or 25, 50, or 75µM of compound 5539-0062 as indicated. Cells were washed, ﬁxed, and examined for YFP
ﬂuorescence by confocal microscopy at 24hours p.t. (c) Standard budding assay and western blotting for Gag in VLPs and cell extracts from
human 293T cells treated with DMSO alone, or the indicated concentrations of PTAP-inhibitor 5539-0062.Advances in Virology 9
[51]. One advantage of L-domain inhibitors is their potential
broad-spectrumactivityagainstawide-arrayofRNAviruses.
Indeed, we were able to show that in addition to inhibiting
budding of eVP40 VLPs, compound 5539-0062 was also able
to block the PTAP-mediated interaction between Tsg101 and
HIV-1 Gag, leading to inhibition of HIV-1 Gag budding.
Although the focus here was on inhibitors of PTAP-type
L-domain activity, similar studies are underway to identify
inhibitors of PPxY-type L-domains as well (Liu, Lee, Olson,
and Harty, unpublished data). Viral PPxY-type L-domains
are known to interact with host proteins such as Nedd4
E3 ubiquitin ligase [4, 24]. One could envision that the
use of a cocktail of budding inhibitors containing both
PTAP- and PPxY-speciﬁc compounds, for example, might be
more eﬀective at blocking virus egress than single L-domain
inhibitors. Indeed, both EBOV and MARV appear to utilize
both PTAP and PPxY L-domains for eﬃcient egress [6, 12].
In addition to these virus-host interaction studies, we are
investigating the contributions of viral VP40-VP40, VP40-
NP, and VP40-VP35 interactions to ﬁlovirus assembly and
egress [5, 7, 32, 52]. The broad applicability of the BiMC
approach as well as a multicolor ﬂuorescence strategy will
enhance our understanding of the biological relevance of
thesecomplexmultiproteininteractionstoRNAvirusegress.
Extension of these studies to include live virus and/or animal
models is essential and will help lead to new insights into
ﬁlovirus pathogenesis and novel treatment options.
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